The Medical University of South Carolina is partnering with an Irish medical technology company to focus on developing solutions that improve health outcomes for patients while reducing costs.
The initial focus of the five-year partnership with Medtronic PLC will be on addressing chronic diseases and acute conditions prevalent in South Carolina, such as cardiovascular disease.
More than 3 million South Carolinians have at least one chronic disease, according to the nonprofit advocacy group Partnership to Fight Chronic Disease, and the projected total cost of chronic disease between 2016 and 2030 in the state is $687 billion.
“Together with MUSC, we are committed to fundamentally improving the way patient care is delivered,” said Omar Ishrak, chairman and CEO of Medtronic, in a statement. “Medtronic has a long history of collaboration with health care providers to invent and develop new markets to solve a variety of clinical problems. The partnership with MUSC is an extension of that collaboration.”
MUSC and Medtronic plan to create several standardized care pathway programs, including programs for vascular disease, joint replacement and respiratory compromise, to establish best practices and streamline processes to improve quality of care.
“This strategic partnership with Medtronic is based on our shared vision and drive to lead the transformation of health care delivery,” said MUSC President Dr. David Cole. “It’s about providing what’s best for our patients. The mutual goal of our organizations is to deliver the best patient outcomes at the lowest cost possible. That’s the true meaning of value-based health care.”
Medtronic also has a partnership with Lehigh Valley Health Network in Allentown, Penn., designed to find ways to improve patient care across more than 70 medical conditions.